2HA Stock Chart & Stats
€1.03
€0.00(0.00%)
At close: 4:00 PM EDT
€1.03
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.90 - €2.59
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€62.89M
Enterprise Value€79.38
Total Cash (Recent Filing)€50.77M
Total Debt (Recent Filing)€2.04M
Price to Earnings (P/E)8.8
Beta1.15
Next Earnings
Nov 16, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding58,234,825
10 Day Avg. Volume200
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.21
Price to Sales (P/S)2.19
P/FCF Ratio-10.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€702.33K
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAnalyst points out that the Phase 3 trial for tebipenem met its primary endpoint early and was stopped for efficacy, strengthening the case for a robust regulatory submission and improved commercial prospects.
Financial Runway And Cost ControlAnalyst observes that reduced research spending after trial completion, together with cash reserves expected to support operations into 2028, lowers near-term financing risk and enhances financial stability.
Partnership MilestonesAnalyst highlights that the licensing agreement with GSK includes multiple milestone payments and tiered royalties that could deliver significant non-dilutive revenue if regulatory and commercial triggers are achieved.
Bears Say
Milestone Payment ReductionAnalyst warns that early trial termination led to a prorated milestone payment materially below initial expectations, reducing anticipated near-term cash inflows from the GSK deal.
Operating LossesAnalyst notes a reported net loss that highlights ongoing operating deficits and raises the possibility of additional financing needs if anticipated partner payments or royalties are delayed.
Spero Therapeutics News
2HA FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was €0.90 and its highest was €2.59 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is €62.89M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Nov 16, 2026 which is in 49 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -€0.138 earnings per share for the quarter.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Overvalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 58,234,825 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -€0.138 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:2HA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
2HA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.View all DE:2HA earnings summariesTechnical Analysis
Inovio Pharmaceuticals
―
NanoViricides
―
Seres Therapeutics
―
PDS Biotechnology
―
Cocrystal Pharma
―